Sociedad Americana de Hirudoterapia

Experience with distal finger replantation: a 20-year retrospective study from a major trauma center

Retrospective cohort published in Tech Hand Up Extrem Surg (2011)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosNazerani S et al. · Techniques in hand & upper extremity surgery, 2011

Abstract

BACKGROUND AND AIM: More than 40 years has passed since the first successfu0l replantation and thousands of fingers have been salvaged. We present our experience with distal finger replantation during 20 years of surgery. From 1990 to 2010, 420 replantations were performed; 64 of 420 cases were distal finger replantations. We discuss the indications, techniques, and outcomes of these difficult cases. METHOD: The records of 64 patients were reviewed and the demographics, methods of replantation, success rates, and complications were evaluated. Bone shortening was performed and fixation method in this zone was mostly pin fixation. The "Bench Technique" for the amputated part consisted of preparing the artery, vein, and nerve. In zones 1 and 2a, the veins are volar and when incising the skin for dissection, utmost care was taken to save the volar delicate veins and prepare them for outflow. When there was no vein found, dissection was toward finding 2 arteries, 1 for inflow and 1 for outflow. Medicinal leeches were used during the first 10 years. Chemical leeching was used thereafter. RESULTS: Our patients were mostly young male workers and from the industrial sector. Our success rate of 87% was similar to the current literature. The overall complication rate from minor wound infection was 35% and total finger loss was 13%. Medicinal leeches had minimal satisfactory results. Chemical leeching was more effective. CONCLUSIONS: Our 20-year experience with distal finger replantation showed a success rate of 87%. On account of cultural beliefs amputation is not tolerated well in Eastern cultures. Thus, a high rate of single finger replantations is seen. The success rate is similar to that of the literature and cosmetic results are far superior to replantation in other zones.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAmputation, TraumaticAnastomosis, SurgicalAnimalsAnticoagulantsAspirinDipyridamoleFemaleFingersHeparin, Low-Molecular-WeightHumansLeeching

Resumen

Over 20 years, 64 of 420 replantations were distal finger replants. Authors reported 87% success rate, comparing medicinal leeches (used during the first 10 years) with chemical leeching (used thereafter) — chemical leeching was more effective in their hands.

Por qué esto importa para la hirudoterapia

This 20-year study reviews records of 64 distal finger replantations performed between 1990 and 2010, reporting an overall success rate of 87%. The abstract notes that medicinal leeches were used during the first 10 years of the study period but had 'minimal satisfactory results,' after which chemical leeching was adopted and found to be more effective. This finding is relevant to ASH's domain as it provides a comparative clinical perspective on medicinal leech use in a surgical context. However, the leech-related assessment is a secondary observation within a broader surgical outcomes study, and the authors' assessment that chemical leeching was superior is not supported by detailed comparative data in the abstract.

Citación

Experience with distal finger replantation: a 20-year retrospective study from a major trauma center.

Nazerani S et al. · Techniques in hand & upper extremity surgery, 2011

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.